These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 10220608)

  • 1. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Comparative economic data regarding lipid-lowering drugs.
    Schwartz JS
    Am Heart J; 1999 May; 137(5):S97-104. PubMed ID: 10220608
    [No Abstract]   [Full Text] [Related]  

  • 2. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Lipid-lowering drugs, cost-effectiveness data, and the formulary system: a health systems perspective.
    Kessler JM
    Am Heart J; 1999 May; 137(5):S111-4. PubMed ID: 10220610
    [No Abstract]   [Full Text] [Related]  

  • 3. The cost-effectiveness of lipid lowering in patients with diabetes: results from the 4S trial.
    Jönsson B; Cook JR; Pedersen TR
    Diabetologia; 1999 Nov; 42(11):1293-301. PubMed ID: 10550412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Economics and cost-effectiveness in evaluating the value of cardiovascular therapy: lipid-lowering therapies--an industry perspective.
    Jackson JD
    Am Heart J; 1999 May; 137(5):S105-10. PubMed ID: 10220609
    [No Abstract]   [Full Text] [Related]  

  • 5. Statins: where are we now?
    Cowie MR
    Hosp Med; 2000 Nov; 61(11):789-92. PubMed ID: 11198749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simvastatin: building on success.
    Gaw A
    Hosp Med; 2001 Jan; 62(1):29-32. PubMed ID: 11211458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.
    Plans-Rubió P
    Am J Cardiovasc Drugs; 2006; 6(3):177-88. PubMed ID: 16780391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-benefit analysis of lipid lowering therapy.
    Davie AP; McMurray JJ
    Eur Heart J; 1996 Jul; 17(7):974-5. PubMed ID: 8809507
    [No Abstract]   [Full Text] [Related]  

  • 9. [Pharmaco-economics of hypolipidemic agents: analysis of factors influencing the cost-effectiveness relation].
    Scheen AJ
    Rev Med Liege; 1998 May; 53(5):270-5. PubMed ID: 9689881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacoeconomics of lipid-lowering drugs.
    Smith DG
    Curr Atheroscler Rep; 2003 Jan; 5(1):67-72. PubMed ID: 12562545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Are the new Lipid Management Guidelines good for Australia's health?
    Jackson RT
    Med J Aust; 2001 Nov; 175(9):452-3. PubMed ID: 11758069
    [No Abstract]   [Full Text] [Related]  

  • 12. Which statin is most efficient for the treatment of hypercholesterolemia? A cost-effectiveness analysis.
    Cobos A; Jovell AJ; García-Altés A; García-Closas R; Serra-Majem L
    Clin Ther; 1999 Nov; 21(11):1924-36. PubMed ID: 10890264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic implications of lipid-lowering trials: current considerations in selecting a statin.
    Farmer JA
    Am J Cardiol; 1998 Sep; 82(6A):26M-31M. PubMed ID: 9766345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simvastatin compared to fluvastatin in the reduction of serum lipids and apolipoproteins in patients with ischaemic heart disease and moderate hypercholesterolaemia.
    Sigurdsson G; Haraldsdottir SO; Melberg TH; Tikkanen MJ; Miettinen TE; Kristianson KJ
    Acta Cardiol; 1998; 53(1):7-14. PubMed ID: 9638964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rationale, design, and baseline results of the Pravastatin-to-Simvastatin Conversion Lipid Optimization Program (PSCOP).
    Ito MK; Stolley SN; Morreale AP; Lin JC; Marcus DB
    Am J Health Syst Pharm; 1999 Jun; 56(11):1107-13. PubMed ID: 10385458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiographic trials of lipid-lowering therapy: end of an era?
    Thompson GR
    Br Heart J; 1995 Oct; 74(4):343-7. PubMed ID: 7488443
    [No Abstract]   [Full Text] [Related]  

  • 17. Cost effectiveness of HMG-CoA reductase inhibitor (statin) treatment related to the risk of coronary heart disease and cost of drug treatment.
    Pickin DM; McCabe CJ; Ramsay LE; Payne N; Haq IU; Yeo WW; Jackson PR
    Heart; 1999 Sep; 82(3):325-32. PubMed ID: 10455083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rosuvastatin is cost-effective in treating patients to low-density lipoprotein-cholesterol goals compared with atorvastatin, pravastatin and simvastatin: analysis of the STELLAR trial.
    Hirsch M; O'Donnell JC; Jones P
    Eur J Cardiovasc Prev Rehabil; 2005 Feb; 12(1):18-28. PubMed ID: 15703502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economics of lipid lowering with HMG CoA reductase inhibitors.
    Illingworth DR
    Clin Cardiol; 1995 Jun; 18(6):295, 363. PubMed ID: 7664501
    [No Abstract]   [Full Text] [Related]  

  • 20. Ezetimibe/Simvastatin: a review of its use in the management of hypercholesterolemia.
    Murdoch D; Scott LJ
    Am J Cardiovasc Drugs; 2004; 4(6):405-22. PubMed ID: 15554726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.